Key Clinical Summary: Personalizing Hemophilia A Treatment

This is a micro-learning module summary of Dr Guy Young’s session which you can find here. Before participating, please read our CME and disclosure information which can be found here.

Acknowledgment: This program is supported by an independent education grant from Bayer. This online education program has been designed for healthcare professionals in the United States only.

Introduction

Treatment options for hemophilia A have expanded significantly in recent years, moving beyond traditional factor replacement therapies to include non-factor rebalancing agents and gene therapy. With this expansion comes the need for thoughtful personalization. Effective treatment selection requires understanding each therapy’s properties, aligning them with patient-specific needs, and revisiting decisions as patients age and their lifestyles evolve.

Treatment Landscape: Key Categories

Available therapies differ widely in mechanism, administration, and frequency:

• Factor VIII replacement (SHL and EHL): IV infusions ranging from 52–183 doses/year depending on product and schedule.
• FVIII mimetics (e.g., emicizumab): Subcutaneous weekly to every 4 weeks.
• Rebalancing agents (fitusiran, concizumab, marstacimab): Subcutaneous, ranging from daily to monthly dosing.
• Gene therapy: One-time IV infusion with the goal of durable FVIII expression.

These distinctions fundamentally shape treatment burden, convenience, and adherence potential.

Shared Decision-Making Framework

Selecting optimal therapy relies on collaborative decision-making. The SHARE model provides structure:

• S: Seek patient participation.
• H: Help patients explore and compare options.
• A: Assess values, preferences, and past experiences.
• R: Reach a decision together.
• E: Evaluate that decision over time and adjust as needed.

This framework encourages transparent discussion of trade-offs and supports long-term engagement with treatment.

Patient Factors Guiding Therapy Selection

Personalization depends on integrating clinical and practical considerations:

1. Demographics and Disease Characteristics

• Age: Many non-factor agents are currently approved only for ≥12 years; gene therapy is available for ≥18 years.
• Severity: Severe, moderate, and mild hemophilia require different prophylaxis strategies.
• Inhibitor status: Limits or expands available options.
• Hemophilia type: A vs B affects which therapies are appropriate.

2. Access, Adherence, and Personal Preferences

• Venous access: Poor access favors subcutaneous options.
• Adherence patterns: Less frequent dosing may benefit inconsistent patients; frequent structured dosing may help those who forget.
• Risk tolerance: Some patients prefer established therapies; others welcome newer agents.
• Lifestyle: High-risk sports or physical occupations may necessitate higher trough protection.
• Joint health and bleed history: Dictates intensity of prophylaxis.

3. Older Adults (>65 years)

• Higher thrombosis risk requires careful therapy choice.
• Comorbidities may influence treatment burden and feasibility.
• Joint disease and mobility impact goals and expectations.

Using Pharmacokinetics (PK) to Tailor Factor Therapy

PK-guided prophylaxis optimizes both bleed protection and factor utilization. Key insights:

• FVIII half-life and clearance vary significantly among individuals.
• Extended half-life FVIII can reduce infusion frequency while maintaining protective troughs.
• PK assessment identifies patients with poor, normal, or good PK profiles, which informs dose and interval selection.
• Good PK may maintain >10–20% FVIII with EHL products; poor PK may require shorter intervals or alternative agents.

Treatment Across the Lifespan

Needs evolve as children grow and lifestyles change:

• Infancy: Priority is safe, early prophylaxis; subcutaneous therapies often preferred to avoid central venous access.
• Early childhood: Frequent falls and head injuries increase bleed risk.
• School-age children: Rising activity levels and sports participation require more robust protection.
• Adolescents: High-risk behaviors and contact sports necessitate personalized intensification.
• Adults: Expanded options include gene therapy; lifestyle and work demands guide choices.

Conclusion

Hemophilia A care has evolved into a landscape rich with options, and personalization sits at its core. Optimal management depends on selecting therapies that align with each patient’s clinical profile, lifestyle, and preferences, while also incorporating PK insights when using factor replacement. Shared decision-making ensures treatment choices reflect what matters most to patients and their families, and revisiting those decisions across the lifespan allows therapy to adapt as needs change. When clinicians integrate these elements thoughtfully, patients benefit from stronger protection, reduced burden, and greater freedom in daily life.

Content is accurate as of the date of release on 6 January 2026.